ERBB2 and breast cancer: The number of patients with ER-positive Her2-negative BC was 390: cALND was performed for 243 patients (62.3%) and the NSN involvement rate with macrometastases was 13.6% (33/243): 9.4% (10/106) and 16.8% (23/137) for patient’s ≤ 50 years and >50 years, respectively (p = 0.950).